Prognostic Implications of Lymphadenectomy in Esophageal Cancer After Neo-adjuvant Therapy: A Single Center Experience

Journal of Gastrointestinal Surgery

Volumn 15, Issue 10, 2011, Pages 1769-1776

  Torgersen, Zachary ^a   Sundaram, Abhishek ^a   Hoshino, Masato ^a   Willer, Brittany ^a   Fang, Xiang ^b   Tashi, Tsewang ^a   Lee, Tommy ^a   Mittal, Sumeet K ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

Chemoradiation; Lymph nodes; Survival

Indexed keywords

ADENOCARCINOMA; ADJUVANT THERAPY; AGED; ARTICLE; DISEASE FREE SURVIVAL; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FEMALE; HUMAN; LYMPHADENECTOMY; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80053111920     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1635-2     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011; 61: 69-90.
2. SEER Stat Fact Sheets: Esophagus. Surveillance Epidemiology and End Results website. http://seer. cancer. gov/statfacts/html/esoph. html. Accessed January 2011.
3. Hyngstrom JR, Posner MC. Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. Journal of Surgical Oncology 2010; 101: 299-304.
4. Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA, Law S, Lerut TE, Reed CE, Salo JA, Scott WJ, Hofstetter WL, Watson TJ, Allen MS, Rusch VW, Blackstone EH. Optimum lymphadenectomy for esophageal cancer. Annals of Surgery 2010; 251: 46-50.
5. Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, Holscher A, Lerut T, Law S, Rice TW, Ruol A, van Lanschot JJ, Wong J, DeMeester TR. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Annals of Surgery 2008; 248: 549-556.
6. Altorki NK, Zhou XK, Stiles B, Port JL, Paul S, Lee PC, Mazumdar M. Total number of resected lymph nodes predicts survival in esophageal cancer. Annals of Surgery 2008; 248: 221-226.
7. Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Annals of Surgery 2008; 247: 365-371.
8. Twine CP, Lewis WG, Morgan MA, Chan D, Clark GW, Havard T, Crosby TD, Roberts SA, Williams GT. The assessment of prognosis of surgically resected oesophageal cancer is dependent on the number of lymph nodes examined pathologically. Histopathology 2009; 55: 46-52.
9. Wilson M, Rosato EL, Chojnacki KA, Chervoneva I, Kairys JC, Cohn HE, Rosato FES, Berger AC. Prognostic significance of lymph node metastases and ratio in esophageal cancer. The Journal of Surgical Research 2008; 146: 11-15.
10. Peyre CG, Hagen JA, DeMeester SR, van Lanschot JJ, Holscher A, Law S, Ruol A, Ancona E, Griffin SM, Altorki NK, Rice TW, Wong J, Lerut T, DeMeester TR. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Annals of Surgery 2008; 248: 979-985.
11. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U. S.: the importance of tumor length and lymph node status. Cancer 2002; 95: 1434-1443.
12. Orringer MB, Marshall B, Chang AC, Lee J, Pickens A, Lau CL. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Annals of Surgery 2007; 246: 363-72; discussion 372-4.
13. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Annals of Surgery 2001; 234: 520-30; discussion 530-1.
14. Luketich JD, Schauer PR, Christie NA, Weigel TL, Raja S, Fernando HC, Keenan RJ, Nguyen NT. Minimally invasive esophagectomy. The Annals of Thoracic Surgery 2000; 70: 906-11; discussion 911-2.
15. Appendix E: Instructions for lymph node dissection. In Rosai J, Ackerman LV, editors. Rosai and Ackerman's surgical pathology, vol. 2, 9th ed. New York: Mosby, 2004, pp 2948.
16. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among White Americans by sex, stage, and age. Journal of the National Cancer Institute 2008; 100: 1184-1187.
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: A Cancer Journal for Clinicians 2009; 59: 225-249.
18. Portale G, Hagen JA, Peters JH, Chan LS, DeMeester SR, Gandamihardja TA, DeMeester TR. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. Journal of the American College of Surgeons 2006; 202: 588-96; discussion 596-8.
19. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, Trans-Tasman Radiation Oncology Group, Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. The Lancet Oncology 2005; 6: 659-668.
20. Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, Song HY, Cho KJ, Kim WK, Lee JS, Kim SH, Min YI. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2004; 15: 947-954.
21. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2008; 26: 1086-1092.
22. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2001; 19: 305-313.
23. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. The New England Journal of Medicine 1996; 335: 462-467.
24. Rice TW, Blackstone EH, Adelstein DJ, Zuccaro G, Jr, Vargo JJ, Goldblum JR, Rybicki LA, Murthy SC, Decamp MM. N1 esophageal carcinoma: the importance of staging and downstaging. The Journal of Thoracic and Cardiovascular Surgery 2001; 121: 454-464.
25. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology-esophageal cancer. Available at http://www. nccn. org/professionals/physician_gls/pdf/esophageal. pdf. Accessed January 2011.
26. Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, Ilson DH, Minsky BD, Rusch VW, American Joint Committee on Cancer. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2007; 25: 507-512.
27. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Annals of Surgery 2005; 241: 810-7; discussion 817-20.